⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TAK News
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
BHVN
NVO
LLY
LXRX
XRTX
REGN
FMS
MDT
AMPH
DRCT
BMRC
MAZE
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
businesswire.com
TAK
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
businesswire.com
TAK
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
businesswire.com
TAK
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight
globenewswire.com
AZN
NVS
ABBV
BMY
GILD
REGN
VRTX
BIIB
JNJ
MRK
ARWR
TAK
VERA
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO ® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
businesswire.com
TAK
eCOA: Has It Lived Up to the Promise? A Realistic Assessment for Today's Trials, Upcoming Webinar Hosted by Xtalks
prnewswire.com
MDT
TAK
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
prnewswire.com
TAK
2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable
prnewswire.com
TAK
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
prnewswire.com
TAK